Evidence map›Paper›PMID 38982894›Full record

ArticleJournal of the International AIDS Society2024

A sub-national HIV epidemic appraisal in Kenya: a new approach for identifying priority geographies, populations and programmes for optimizing coverage for HIV prevention.

Ramesh Banadakoppa Manjappa, Parinita Bhattacharjee, Souradet Yuh-Nan Shaw, Joshua Gitonga, Japheth Kioko, Franklin Songok, Faran Emmanuel, Peter Arimi, Helgar Musyoki, Ruth Laibon Masha and 1 more

Abstract read
In one paragraph

Article in Journal of the International AIDS Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ramesh Banadakoppa ManjappaInstitute for Global Public Health, University of Manitoba, Winnipeg, Manitoba, Canada.ORCID https://orcid.org/0000-0003-3038-4415
Parinita BhattacharjeeInstitute for Global Public Health, University of Manitoba, Winnipeg, Manitoba, Canada.ORCID https://orcid.org/0000-0003-3277-7693
Souradet Yuh-Nan ShawInstitute for Global Public Health, University of Manitoba, Winnipeg, Manitoba, Canada.ORCID https://orcid.org/0000-0002-0982-1302
Joshua GitongaNational Syndemic Diseases Control Council, Ministry of Health, Nairobi, Kenya.
Japheth KiokoPartners for Health and Development in Africa, Nairobi, Kenya.
Franklin SongokNational AIDS and STI Control Programme, Ministry of Health, Nairobi, Kenya.
Faran EmmanuelInstitute for Global Public Health, University of Manitoba, Winnipeg, Manitoba, Canada.
Peter ArimiPartners for Health and Development in Africa, Nairobi, Kenya.
Helgar MusyokiGlobal Fund to Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland.
Ruth Laibon MashaNational Syndemic Diseases Control Council, Ministry of Health, Nairobi, Kenya.
James BlanchardInstitute for Global Public Health, University of Manitoba, Winnipeg, Manitoba, Canada.

Funding

Bill & Melinda Gates Foundation
6 · The paper itself

Abstract

introductionThe HIV Prevention 2025 Roadmap, developed by UNAIDS, recommends the adoption of a precision prevention approach focused on priority populations and geographies. With reduction in new HIV acquisitions in many countries, designing a differentiated HIV prevention response, using a Programme Science approach, based on the understanding of the epidemic and transmission dynamics at a sub-national level, is critical.

methodsTo support strategic planning, an epidemic appraisal at the sub-national level across 47 counties, with the 2019 population ranging from 0.14 million in Lamu to 4.40 million in Nairobi City, was conducted in Kenya using several existing data sources. Using 2021 Spectrum/EPP/Naomi model estimates of national and sub-national HIV incidence and prevalence, counties with high HIV incidence and prevalence were identified for geographic prioritization. The size of local key population (KP) networks and HIV prevalence in key and general populations were used to define epidemic typology and prioritize populations for HIV prevention programmes. Analysis of routine programme monitoring data for 2021 was used to assess coverage gaps in HIV prevention programmes, including prevention of vertical transmission, anti-retroviral therapy, KP programmes, adolescent girls and young women programme, and voluntary male medical circumcision programme.

resultsTen counties with more than 1000 incident acquisitions in 2021 accounted for 57% of new acquisitions. Twenty-four counties were grouped into the concentrated epidemic type-due to their low prevalence in the general population, high prevalence in KPs and relatively higher density of female sex workers and men who have sex with men populations. Four counties reflected a generalized epidemic, where HIV prevalence was more than 10% and 30%, respectively, among the general and key populations. The remaining 19 counties were classified as having mixed epidemics. Gaps in programmes were identified and counties where these gaps need to be addressed were also prioritized.

conclusionsThe HIV burden in Kenya is unevenly distributed and hence the mix of prevention strategies may vary according to the epidemic typology of the county. Prioritization of programmes based not only on disease burden and epidemic typology, but also on the prevailing gaps in coverage for reducing inequities is a key aspect of this appraisal.

Indexed as

HIV InfectionsAdolescentAdultEpidemicsFemaleHumansIncidenceKenyaMalePrevalenceYoung AdultHIV epidemic appraisalHIV epidemiologyHIV preventionsub‐national

Identifiers

PMID38982894
PMCPMC11233855

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.